These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 16868063

  • 1. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
    Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2006 Oct; 91(10):3970-80. PubMed ID: 16868063
    [Abstract] [Full Text] [Related]

  • 2. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S, Cognigni GE, Filicori M, Morselli-Labate AM.
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [Abstract] [Full Text] [Related]

  • 3. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Gambineri A, Pelusi C, Genghini S, Morselli-Labate AM, Cacciari M, Pagotto U, Pasquali R.
    Clin Endocrinol (Oxf); 2004 Feb; 60(2):241-9. PubMed ID: 14725687
    [Abstract] [Full Text] [Related]

  • 4. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F, Zamani MM, Heshmat R, Moini nia F.
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome.
    Gambineri A, Patton L, De Iasio R, Cantelli B, Cognini GE, Filicori M, Barreca A, Diamanti-Kandarakis E, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3854-62. PubMed ID: 15827099
    [Abstract] [Full Text] [Related]

  • 6. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
    Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R.
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2670-8. PubMed ID: 18460557
    [Abstract] [Full Text] [Related]

  • 7. Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
    Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.
    Int J Obes (Lond); 2008 Apr; 32(4):692-9. PubMed ID: 18071341
    [Abstract] [Full Text] [Related]

  • 8. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

  • 9. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
    Ibáñez L, de Zegher F.
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
    [Abstract] [Full Text] [Related]

  • 10. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
    Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2600-6. PubMed ID: 12788862
    [Abstract] [Full Text] [Related]

  • 11. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J, Zhu Y, Jiang Y, Cao Y.
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [Abstract] [Full Text] [Related]

  • 12. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
    Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M.
    J Clin Endocrinol Metab; 2000 Jan; 85(1):139-46. PubMed ID: 10634377
    [Abstract] [Full Text] [Related]

  • 13. Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
    Jensterle M, Kocjan T, Janez A.
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1476-81. PubMed ID: 24823465
    [Abstract] [Full Text] [Related]

  • 14. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
    Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE.
    Fertil Steril; 2004 Oct; 82(4):893-902. PubMed ID: 15482765
    [Abstract] [Full Text] [Related]

  • 15. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA, Khurana ML, Nisar S, Shah PA, Shah ZA, Kulshrestha B, Gupta N, Zargar MA, Wani TA, Mudasir S, Mir FA, Taing S.
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [Abstract] [Full Text] [Related]

  • 16. Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
    Sahin I, Serter R, Karakurt F, Demirbas B, Culha C, Taskapan C, Kosar F, Aral Y.
    Gynecol Endocrinol; 2004 Sep; 19(3):115-24. PubMed ID: 15697072
    [Abstract] [Full Text] [Related]

  • 17. Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
    Pagotto U, Gambineri A, Vicennati V, Heiman ML, Tschöp M, Pasquali R.
    J Clin Endocrinol Metab; 2002 Dec; 87(12):5625-9. PubMed ID: 12466363
    [Abstract] [Full Text] [Related]

  • 18. Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
    Ibáñez L, De Zegher F.
    Hum Reprod; 2004 Aug; 19(8):1725-7. PubMed ID: 15229206
    [Abstract] [Full Text] [Related]

  • 19. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D, Farmakiotis D, Rousso D, Kourtis A, Katsikis I, Krassas G.
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
    Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF.
    Hum Reprod; 2007 Nov; 22(11):2967-73. PubMed ID: 17766923
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.